Mirum Pharmaceuticals, Inc. MIRM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $569.61M+50.2% | $521.31M+54.7% | $471.79M+53.7% | $429.16M+62.3% | $379.25M+69.3% | ||
| $238.04M+59.3% | $181.18M+28.8% | $174.1M+36.5% | $162.85M+33.5% | $149.45M+34.3% | ||
| $295.65M+38.0% | $257.03M+27.1% | $239.73M+25.1% | $228.37M+28.6% | $214.29M+32.9% | ||
| $1.37B+200% | $543.45M+28.0% | $513.59M+27.4% | $486.24M+30.4% | $455.57M+37.0% | ||
| -$796.42M-944% | -$22.14M+74.7% | -$41.79M+56.5% | -$57.08M+47.4% | -$76.32M+29.6% | ||
| -139.8%-120pp | -4.2%+21.8pp | -8.9%+22.4pp | -13.3%+27.7pp | -20.1%+28.3pp | ||
| $14.41M+0.6% | $14.39M+0.5% | $14.37M+0.5% | $14.35M+0.5% | $14.33M-0.8% | ||
| $481K-69.2% | $2.59M+113% | $2.82M+236% | $1.34M+305% | $1.56M+711% | ||
| -$797.46M-951% | -$21.43M+75.3% | -$40.83M+58.3% | -$57.36M+46.6% | -$75.91M+51.7% | ||
| $1.38M— | $1.94M— | —— | —— | —— | ||
| -$798.84M-933% | -$23.36M+73.4% | -$41.42M+58.5% | -$58.56M+46.4% | -$77.34M+51.2% | ||
| -140.2%-120pp | -4.5%+21.6pp | -8.8%+23.7pp | -13.6%+27.6pp | -20.4%+50.4pp | ||
| -$13.62-746% | -$0.49+73.5% | -$0.86+58.7% | -$1.21+48.5% | -$1.61+57.3% | ||
| -$771.35M-1,375% | $2.11M+103% | -$17.57M+75.9% | -$32.86M+63.0% | -$52.3M+44.0% | ||
| -135.4%-122pp | 0.4%+19.4pp | -3.7%+20.0pp | -7.7%+25.9pp | -13.8%+27.9pp | ||
| -$796.42M-944% | -$22.14M+74.7% | -$41.79M+56.5% | -$57.08M+47.4% | -$76.32M+29.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) generated $569.6M in revenue over the trailing twelve months, up 50.2% year over year.
- Is Mirum Pharmaceuticals, Inc. profitable?
- Mirum Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $798.8M over the trailing twelve months, a -140.2% net margin.
- What is Mirum Pharmaceuticals, Inc.'s earnings per share?
- Mirum Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-13.62.
- Where does Mirum Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
